Amarin reported $-15697000 in Net Income for its fiscal quarter ending in March of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amarin USD -15697000 32.92M Mar/2025
AstraZeneca USD 2.45B 466M Jun/2025
DBV Technologies USD -41875000 14.8M Jun/2025
GlaxoSmithKline GBP 1.44B 181M Jun/2025
Halozyme Therapeutics USD 165.16M 47.06M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025